Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Conditions: Advanced Malignant Solid Neoplasm; ARAF Gene Mutation; BRAF Gene Mutation; GNA11 Gene Mutation; GNAQ Gene Mutation; HRAS Gene Mutation; KRAS Gene Mutation; MAP2K1 Gene Mutation; MAPK1 Gene Mutation; NF1 Gene Mutation; NRAS Gene Mutation; Re current Ependymal Tumor; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Central Nervous System Neoplasm; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma ; Recurrent Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Histiocytic and Dendritic Cell Neoplasm; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Central Nervous System Neoplasm; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bone Cancers | Brain | Brain Tumor | Cancer & Oncology | Ependymoma | Glioma | Hepatoblastoma | Histiocytosis | Lymphoma | Medulloblastoma | Neuroblastoma | Neurology | Non-Hodgkin's Lymphoma | Osteosarcoma | Pediatrics | Rhabdomyosarcoma | Sarcomas | Study